In vitro α-glucosidase inhibitory activity of Tamarix nilotica shoot extracts and fractions

alpha-glucosidase inhibitors represent an important class of type 2 antidiabetic drugs and they act by lowering postprandial hyperglycemia. Today, only three synthetic inhibitors exist on the market, and there is a need for novel, natural and more efficient molecules exhibiting this activity. In this study, we investigated the ability of Tamarix nilotica ethanolic and aqueous shoot extracts, as well as methanolic fractions prepared from aqueous crude extracts to inhibit alpha-glucosidase. Both, 50% ethanol and aqueous extracts inhibited alpha-glucosidase in a concentration-dependent manner, with IC50 values of 12.5 mu g/mL and 24.8 mu g/mL, respectively. Importantly, alpha-glucosidase inhibitory activity observed in the T. nilotica crude extracts was considerably higher than pure acarbose (IC50 = 151.1 mu g/mL), the most highly prescribed alpha-glucosidase inhibitor on the market. When T. nilotica crude extracts were fractionated using methanol, enhanced alpha-glucosidase inhibitory activity was observed in general, with the highest observed alpha-glucosidase inhibitory activity in the 30% methanol fraction (IC50 = 5.21 mu g/mL). Kinetic studies further revealed a competitive reversible mechanism of inhibition by the plant extract. The phytochemical profiles of 50% ethanol extracts, aqueous extracts, and the methanolic fractions were investigated and compared using a metabolomics approach. Statistical analysis revealed significant differences in the contents of the crude extracts and fractions and potentially identified the molecules that were most responsible for these observed variations. Higher alpha-glucosidase inhibitory activity was associated with an enrichment of terpenoids, fatty acids, and flavonoids. Among the identified molecules, active compounds with known alpha-glucosidase inhibitory activity were detected, including unsaturated fatty acids, triterpenoids, and flavonoid glycosides. These results put forward T. nilotica as a therapeutic plant for type 2 diabetes and a source of alpha-glucosidase inhibitors.